Inogen Inc
About Inogen Inc
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $295.3M
- Net income
- -$22.7M
- Total assets
- $298.6M
- Market cap
- $173.5M
- Gross margin
- 44.2%
- Operating margin
- -8.7%
- Net margin
- -6.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $348.7M
- Cost of revenue
- $194.4M
- Gross profit
- $154.3M
- Operating expenses
- $184.5M
- Operating income
- -$30.2M
- Income tax
- -$632.0K
- Net income
- -$22.7M
- EPS (basic)
- $-0.86
- EPS (diluted)
- $-0.86
Balance sheet
- Total assets
- $298.6M
- Current assets
- $198.3M
- Total liabilities
- $106.4M
- Current liabilities
- $63.5M
- Shareholders’ equity
- $192.2M
Cash flow
- Operating cash flow
- -$11.2M
- Investing cash flow
- -$26.2M
- Financing cash flow
- $24.2M
- Net cash flow
- -$13.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $173.5M
- EPS (diluted)
- $-0.86
- Shares outstanding
- 28.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 14, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.7M in FY2025.
- Revenue grew 13% from FY2020 to FY2025.
- Gross margin of 44.2%, net margin -6.5%.
- Trading 32% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inogen Inc.
Write a review
News about Inogen Inc
News & sentiment via Polygon.io
